 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...161162163164165166167168169170171...235236» |
- leucovorin calcium / Generic mfg., Vectibix (panitumumab) / Amgen, Takeda
Circulating tumor DNA (ctDNA) heterogeneity as first- and third-line treatment in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab. (Level 1, West Hall - Poster Board L16) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_987;
Panitumumab monotherapy in the 3L setting appears to induce greater RAS-specific selective pressure than panitumumab FOLFOX4 combination therapy in 1L, resulting in increased RAS mutations at FU in the 3L setting. The combination of panitumumab + FOLFOX in 1L is associated with delayed emergence of expansion of RAS mutations compared to later line single agent panitumumab.
- Avastin (bevacizumab) / Roche, irinotecan / Generic mfg., Modufolin (arfolitixorin) / Isofol Medical
Plasma deoxyuridine levels in metastatic colorectal cancer (mCRC) patients and clinical response after 5FU based therapy in combination with arfolitixorin. (Level 1, West Hall - Poster Board J5) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_935;
P1/2
dUr could potentially be an early surrogate marker for TS inhibition in mCRC patients treated with 5FU/arfolitixorin. Clinical trial information: NCT02244632.
- leucovorin calcium / Generic mfg.
Pilot study of the safety and feasibility of immediate adjuvant chemotherapy (IAC) in nonmetastatic colonic adenocarcinoma (nmCC). (Level 1, West Hall - Poster Board G14) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_901;
Further prospective studies are needed to explore the oncologic benefit of this novel systemic treatment approach. Research Funding: Chao Family Comprehensive Cancer Center Pilot Project
- Avastin (bevacizumab) / Roche, irinotecan / Generic mfg.
A phase II study of FOLFOXIRI plus bevacizumab (Bmab) as initial chemotherapy for patients (pts) with untreated metastatic colorectal cancer (mCRC): TRICC1414 (Be TRI). (Level 1, West Hall - Poster Board F20) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_885;
P2
Clinical trial information: NCT02497157. Research Funding: None
- Efficacy and safety of the combination of aflibercept with fluorouracil, leucovorin, and irinotecan in patients aged 70 years and older with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen in Spain: A retrospective multicenter cohort study. (Level 1, West Hall - Poster Board F10) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_875;
Aflibercept plus FOLFIRI is a good therapeutic option for the treatment of mCRC in patients aged 70 years and older previously treated with oxaliplatin. Research Funding: None
- leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Optimizing FOLFIRINOX tolerability in patients with colorectal cancer through dosing irinotecan in the morning for men and in the afternoon for women. (Level 1, West Hall - Poster Board F6) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_871;
Prospective trials testing sex specific timing issues are warranted. Clinical trial information: 05011.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
mFOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: The FOCULM study. (Level 1, West Hall - Poster Board E7) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_850;
P2
Clinical trial information: NCT02063529. Research Funding: None
- Real-world data on treatment patterns of advanced CRC in third-line and beyond. (Level 1, West Hall - Poster Board C6) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_811;
Recycling of chemotherapy and biologics in the late line setting is common and occurs more frequently than switching to a drug regimen with an alternative mechanism of action. Research Funding: NantHealth
- leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
The comparison of mFOLFOXIRI with CAOX/SOX as neoadjuvant chemotherapy for locally advanced rectal cancer. (Level 1, West Hall - Poster Board C1) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_806;
Although the pathological response of mFOLFOXIRI was comparable with CAPOX/SOX, CAPOX/SOX was less toxic.The further investigation including 5 year overall survival rate rate was needed. Research Funding: None
- oxaliplatin / Generic mfg., Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda, Servier
A phase II, open-label pilot study evaluating the safety and activity of Nal-IRI in combination with 5-FU and oxaliplatin in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study) (NCT03483038). (Level 1, West Hall - Poster Board Q11) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_761;
P2
Clinical trial information: NCT03483038. Research Funding: IPSEN
- Graspa (eryaspase) / ERYtech, irinotecan / Generic mfg.
TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). (Level 1, West Hall - Poster Board Q4) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_755;
P3
Clinical trial information: NCT03665441. Research Funding: Erytech
- Hutruo (bermekimab IV) / J&J, Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda, Servier
A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX). (Level 1, West Hall - Poster Board Q1) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_752;
P1
Clinical trial information: NCT03207724. Research Funding: Ipsen and XBiotech, Inc
- Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda, Servier
Phase II study of nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil (5-FU)/folinic acid (FA) in refractory advanced high-grade neuroendocrine cancer (HG-NEC) of gastroenteropancreatic (GEP) or unknown origin. (Level 1, West Hall - Poster Board P19) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_748;
P2
Advanced GEP or unknown origin HG-NEC pts with progressive disease/intolerance to 1st line Rx with EP or temozolomide/capecitabine; ECOG PS 0-2 would receive nal-IRI 70 mg/m2, FA 400 mg/m2 followed by 5-FU 2400 mg/m2 on D1 & 15 of 28-days cycle...Clinical trial information: NCT03736720. Research Funding: Ipsen Pharmaceuticals, Other Foundation
- Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda, Servier
Phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2). (Level 1, West Hall - Poster Board P6) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_735;
P2
Although there is no established second-line treatment, regimens such as FOLFOX, XELOX, FOLFIRI, XELIRI, GEM, and capecitabine have activity...Clinical trial information: NCT04005339. Research Funding: Ipsen
- leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Pancreatic cancer intratumoral microbiome and characteristics within paired patient samples. (Level 1, West Hall - Poster Board M11) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_695;
In future studies, intra-tumoral microbiome may be more relevant to associations with outcomes and treatment response than stool or intestinal microbiome studies. Research Funding: None
- leucovorin calcium / Generic mfg., Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda, Servier
DNA-damage repair deficiency (dDDR) and response to nanoliposomal irinotecan (nal-IRI) in metastatic pancreatic ductal adenocarcinoma (mPDAC). (Level 1, West Hall - Poster Board L20) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_683;
The PFS and CBR were numerically but not statistically superior, especially in patients with germline DDR mutations. Larger data sets and longer follow-up are needed to confirm this trend.
- leucovorin calcium / Generic mfg., Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda, Servier
Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis. (Level 1, West Hall - Poster Board H13) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_616;
In this cohort, well known prognostic markers has been confirmed, as expected. Research Funding: None
- leucovorin calcium / Generic mfg.
Tumor treating fields (TTFields; 150 kHz) and FOLFOX combination treatment effects on gastric cancer in vitro. (Level 1, West Hall - Poster Board F17) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_346;
There is a strong rational to continue exploring the use of TTFields in combination with standard of care for gastric cancer treatment in the clinical settings. Research Funding: Novocure
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., docetaxel / Generic mfg.
Neoadjuvant chemotherapy with docetaxel plus oxaliplatin and S-1 for locally advanced, resectable gastric or gastro-esophageal junction adenocarcinoma: Short-term results from a phase II trial. (Level 1, West Hall - Poster Board F8) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_337;
Long-term results will be published in two years. Clinical trial information: 000017652.
- oxaliplatin / Generic mfg., gimeracil +oteracil +tegafur +folinic acid (TAS-118) / Otsuka
Feasibility and pathological response of TAS-118 + oxaliplatin as perioperative chemotherapy for patients with locally advanced gastric cancer (APOLLO-11). (Level 1, West Hall - Poster Board D6) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_291;
P3
Clinical trial information: 000024688. Research Funding: Taiho
- Graspa (eryaspase) / ERYtech, irinotecan / Generic mfg.
TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). (Level 1, West Hall - Poster Board Q4) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_182;
P3
Clinical trial information: NCT03665441. Research Funding: Erytech
- pegilodecakin (LY3500518) / Eli Lilly
Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA). (Level 2, Ballroom) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_164;
P3
Safety findings were consistent with previous data observed from PEG + chemotherapy; toxicity was manageable and tolerable. Clinical trial information: NCT02923921.
- | Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 10, 2019
P1/2, N=43, Recruiting, Sponsor: Aadi, LLC
Clinical trial information: NCT02923921. Trial completion date: Apr 2021 --> Dec 2021 | Trial primary completion date: Apr 2020 --> Dec 2020
- |||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: TRIPLET: A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (clinicaltrials.gov) - Dec 9, 2019
P2, N=84, Recruiting, Sponsor: Sun Yat-sen University
- || Enrollment open, Metastases: Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine (clinicaltrials.gov) - Dec 9, 2019
P2, N=42, Recruiting, Sponsor: HonorHealth Research Institute
Trial completion date: Apr 2021 --> Dec 2021 | Trial primary completion date: Apr 2020 --> Dec 2020 Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: NOM-ERA: Non-Operative Management and Early Response Assessment in Rectal Cancer (clinicaltrials.gov) - Dec 9, 2019
P=N/A, N=68, Not yet recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial completion date: Oct 2024 --> Jan 2025 | Initiation date: Oct 2019 --> Jan 2020 | Trial primary completion date: Apr 2023 --> Jul 2023
- || leucovorin calcium / generics, fluorouracil / generics, gemcitabine / generics
Clinical, Journal: Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. (Pubmed Central) - Dec 8, 2019
Trial completion date: Oct 2024 --> Jan 2025 | Initiation date: Oct 2019 --> Jan 2020 | Trial primary completion date: Apr 2023 --> Jul 2023 Capecitabine or S-1 can be used as a second-line treatment for patients with advanced pancreatic cancer with poor performance status after progression to a gemcitabine-based regimen.
- leucovorin calcium / Generic mfg.
The Effect of Folinic Acid (FA) Rescue Following MTX Gvhd Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: A Double Blind Randomized Controlled Study (World Center Marriott - Palms: Royal) - Dec 8, 2019 - Abstract #TCTASTCTCIBMTR2020TCT_680;
The interim results, showing similar rates of grade 3-4 OM and secondary outcomes, do not support continuation of the study. FA-rescue following MTX GVHD prophylaxis does not seem to decrease regimen related toxicity and affect transplant outcomes.
- | Enrollment closed, Trial completion date: A Phase II Study of Neoadjuvant FOLFIRINOX (clinicaltrials.gov) - Dec 6, 2019
P2, N=48, Active, not recruiting, Sponsor: Indiana University
FA-rescue following MTX GVHD prophylaxis does not seem to decrease regimen related toxicity and affect transplant outcomes. Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Jun 2020
- || Trial completion date, Trial primary completion date: MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov) - Dec 5, 2019
P1/2, N=205, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Jun 2020 Trial completion date: Sep 2020 --> Feb 2022 | Trial primary completion date: Nov 2019 --> Feb 2022
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 5, 2019
P2, N=53, Suspended, Sponsor: Children's Oncology Group
Trial completion date: Sep 2020 --> Feb 2022 | Trial primary completion date: Nov 2019 --> Feb 2022 Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020
- | sorafenib / Generic mfg.
Trial completion, Metastases: Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC (clinicaltrials.gov) - Dec 5, 2019
P3, N=247, Completed, Sponsor: Sun Yat-sen University
Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020 Active, not recruiting --> Completed
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2019
P1, N=32, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Mar 2020 --> Nov 2019 | Trial primary completion date: Mar 2020 --> Nov 2019
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Combination therapy, Metastases: D6070C00005: MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. (clinicaltrials.gov) - Dec 5, 2019
P1b/2, N=310, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed | Trial completion date: Mar 2020 --> Nov 2019 | Trial primary completion date: Mar 2020 --> Nov 2019 Recruiting --> Active, not recruiting
- | Cyramza (ramucirumab) / Eli Lilly
Enrollment closed, Enrollment change, Combination therapy: FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (clinicaltrials.gov) - Dec 4, 2019
P2/3, N=180, Active, not recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=908 --> 180
- | Enrollment open, Trial initiation date: DIRECT: A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer (clinicaltrials.gov) - Dec 4, 2019
P3, N=528, Recruiting, Sponsor: Angiodynamics, Inc.
Recruiting --> Active, not recruiting | N=908 --> 180 Not yet recruiting --> Recruiting | Initiation date: May 2019 --> Dec 2019
- ||| Lumakras (sotorasib) / Amgen
New P1 trial, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Dec 3, 2019
P1b, N=120, Not yet recruiting, Sponsor: Amgen
- | Bavencio (avelumab) / EMD Serono
Enrollment change, Trial suspension, Combination therapy, Metastases: Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 (clinicaltrials.gov) - Dec 3, 2019
P2, N=27, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: May 2019 --> Dec 2019 N=97 --> 27 | Recruiting --> Suspended
- || paclitaxel / Generic mfg.
Clinical, P2 data, Journal: Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. (Pubmed Central) - Nov 30, 2019
Our study failed to validate the predefined early metabolic response for pCR to neoadjuvant chemoradiotherapy in locally advanced ESCC patients. However, postchemotherapy SUV may be prognostic and predictive, and warrants further study.
- || methotrexate / Generic Mfg.
Review, Journal: The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: A systematic review. (Pubmed Central) - Nov 29, 2019
However, postchemotherapy SUV may be prognostic and predictive, and warrants further study. Even though future studies are necessary, higher cumulative Leucovorin doses and early initiation of Leucovorin after start of MTX seem to reduce oral mucositis.
- | methotrexate / Generic Mfg.
Review, Journal: A 2018 Approach to Combating Methotrexate Toxicity Folic Acid and Beyond. (Pubmed Central) - Nov 29, 2019
There are, however, more potential strategies in a rheumatologist's armamentarium to ameliorate side effects and improve adherence, including vitamin A supplementation and dextromethorphan. Herein, we will provide a review of the literature (both rheumatologic and oncologic) and expert opinion in terms of managing methotrexate toxicity and improving adherence in rheumatic diseases.
- || cisplatin / Generic Mfg.
Clinical, Journal, Microsatellite Instability, MSi-H Biomarker, PD(L)-1 Biomarker, IO Biomarker: Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. (Pubmed Central) - Nov 29, 2019
Moreover, tumor PD-L1 expression ≥1% was associated with greater benefit from intensive sequential chemotherapy compared with 5-fluorouracil plus leucovorin (5-FU/LV), whereas PD-L1 expression <1% was not, conditioning a statistically significant interaction between such biomarker and treatment arms. The meta-analysis of individual patients' data from available studies could yield data on the role of MSI status that could inform clinical decisions.
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment status: mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer (clinicaltrials.gov) - Nov 26, 2019
P3, N=300, Enrolling by invitation, Sponsor: Huashan Hospital
The meta-analysis of individual patients' data from available studies could yield data on the role of MSI status that could inform clinical decisions. Recruiting --> Enrolling by invitation
- | Cyramza (ramucirumab) / Eli Lilly
Enrollment open, Metastases: RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov) - Nov 26, 2019
P2/3, N=429, Recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Recruiting --> Enrolling by invitation Active, not recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, New P2 trial, Liquid biopsy, Biopsy: PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Nov 25, 2019
P2, N=278, Recruiting, Sponsor: Judith Dixon-Hughes
- | Trial completion, Trial completion date, Trial primary completion date: Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Nov 25, 2019
P2, N=44, Completed, Sponsor: Asan Medical Center
Active, not recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Jun 2019 --> Nov 2019 | Trial primary completion date: Oct 2018 --> Sep 2019
- methotrexate / Generic Mfg.
RELATIONSHIP OF PEAK SERUM METHOTREXATE CONCENTRATION AND DRUG TOXICITIES IN EXTREMITY OSTEOSARCOMAS () - Nov 23, 2019 - Abstract #AIOM2019AIOM_114;
Our results suggest that C max did not correlated significantly with toxicities and complications. However we believe that our data should be confirmed by further study with greater number of patients.
- leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
NLR (NEUTROPHIL/LYMPHOCYTE RATIO) AND SECOND LINE CHEMOTHERAPY WITH FOLFIRI FOR PATIENTS WITH METASTATIC PANCREATIC CANCER: OUR EXPERIENCE () - Nov 23, 2019 - Abstract #AIOM2019AIOM_48;
FOLFIRI regimen in 2nd line showed a modest activity and discrete tolerance in this setting.NLR <5, in our experience, is correlated to a better prognosis. We are expecting new prognostic factors could be a guidance to choice the treatment.
- leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
MODIFIED FOLFIRINOX FOR UNRESECTABLE LOCALLY ADVANCED/METASTATIC PANCREATIC CANCER. A REAL-WORLD COMPARISON OF AN ATTENUATED WITH A FULL DOSE IN A SINGLE CENTRE EXPERIENCE () - Nov 23, 2019 - Abstract #AIOM2019AIOM_47;
However neutropenia, anemia, fatigue and vomiting were statistically increased in the 18 patients receiving a full dose compared with the 32 patients receiving an attenuated dose of FOLFIRINOX (p<0,05). This study demonstrates the efficacy and tolerability of modified FOLFIRINOX in advanced/metastatic pancreatic cancer.
- oxaliplatin / Generic Mfg., Abraxane (albumin-bound paclitaxel) / Otsuka, BMS
OXALIPLATIN-BASED THERAPY AND ECOG PERFORMANCE STATUS (PS) ARE PREDICTIVE OF SURVIVAL IN SECOND-LINE ADVANCED PANCREATIC CANCER (PC) AFTER GEMCITABINE PLUS NAB-PACLITAXEL TREATMENT () - Nov 23, 2019 - Abstract #AIOM2019AIOM_42;
Pts receiving an oxaliplatin-based chemotherapy and with PS ECOG = 0 had a longer OS in the second-line setting. However, no differences have been shown considering PFS and no analyses have been performed regarding different regimens (e.g. irinotecan versus nal-IRI) because of the limited number of pts included.